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As we stand in the early years of the 21st century, with hundreds of antihypertensive 
drugs at our disposal, it is difficult to believe that 60 years ago there was absolutely 
nothing available for the treatment of hypertension.  In fact, it was not even universally 
accepted that the “benign” or “essential” hypertension needed to be treated, unless it 
entered the malignant phase.  At that point, it was treated with desperate measures, 
such as pyrogens or poisons causing circulatory shock or with radical surgical proce-
dures, such as severance of sympathetic tracts or bilateral adrenalectomy.
Throughout the 150s and 160s several classes of antihypertensive agents became 
available and were tested in clinical trials.  The results indicated not only that lower-
ing elevated blood (BP) was beneficial, but also that the optimal BP target was much 
lower than the initial target of 160/5, which was later set at 140/0 and more recently 
at 130/80, whereas normal BP is now considered to be 120/80 or less.  Indeed, several 
studies have now confirmed that average differences of 10/5 mmHg may translate into 
decreases of 20-40% in the rate of cardiovascular and cerebrovascular complications. 
However, it also became apparent that optimal targets could rarely be reached by 
monotherapy and indeed required multiple drugs in various combinations, leading 
patients to confusion, expense, denial.  This led to the idea that the best way to over-
come patient resistance may be fixed combinations of two or more drugs in a single 
pill or capsule.  The earliest such two- or three-drug combinations appeared in the 
150s and consisted mostly of a diuretic, a sympatholytic and a vasodilator—whatever 
was available at the time.
With further research into mechanisms of action and development of new drugs, it 
became evident that the most effective combinations were those, whose mechanisms 
are complementary or synergistic.  An example of this is rendering the BP renin-de-
pendent by removing salt with diuretics, so that angiotensin-inhibiting agents become 
greatly potentiated.  Others have simply additive, or even less than additive effect, but 
may prevent each other’s adverse effects, such as combination of a kaliuretic with a 
potassium-sparing diuretic.  Others yet, have the capacity to treat frequently coexist-
ing conditions, such as high BP and dyslipidemia, with a single pill.  Thus, the pills 
containing a fixed drug combination have evolved from random (whatever happens 
to be available), to rational (complementary or synergistic) and expedient (concurrent 
treatment of co-morbidities).  And the use of these combinations is gaining ground 
not only for treatment of hypertension, but also for related disorders, such as coro-
nary artery disease, where initial treatment of acute coronary syndrome  or chronic 
preventive treatment of coronary risk factors was proposed with the “tetrapill” or 
“polypill,” i.e., various fixed combinations containing a diuretic, an ACE inhibitor, 
a beta-adrenoceptor blocker, a statin and low-dose aspirin.  Even if the more distant 
future may promise personalized therapy based on pharmacogenetics, the current 
AtHENs cArDIOLOGY UPDAtE 2008
Boston University School of Medicine, 
Boston, MA, USA
HOSPITAL CHRONICLES 2008, SUPPLEMENT: 208–20
Address for correspondence:
E-mail: hgavras@bu.edu
FIXED COMBINATIONS IN ANTIHYPERTENSIVE THERAPY
20
availability of rational fixed drug combinations is a practical 
and convenient approach for today’s clinical practice.
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